Cannabinoid Restricted: UN Includes HHC in Schedule II of the Convention on Psychotropic Substances

According to CannaReporter, the decision was made during the Commission's session held in Vienna, with the only abstention from the United States.

Currently marketed as a substitute for THC, HHC will be restricted to scientific and medical uses, as established in Schedule II. This represents an international prohibition on the recreational and non-medical use of the substance. During the meeting, it was highlighted that HHC can be consumed by inhalation, orally, and sublingually, and that its presence has been detected in drivers operating under its influence. In February of this year, Sechat had already reported that this decision would take place in March.

Approval and Voting

The recommendation was approved with the requirement of a two-thirds majority, or 36 votes in favor. In addition to the abstention from the United States, the following countries voted in favor: Algeria, Argentina, Australia, Brazil, Canada, Chile, China, France, India, Japan, Portugal, the United Kingdom, and others. The inclusion of HHC in Schedule II implies the implementation of prescription and licensing regimes for its production and distribution, impacting all 184 signatory countries of the convention.

Technical Discussions on HHC

The decision was based on data presented during the session, which indicated that HHC can be consumed through various routes, such as inhalation, oral, and sublingual. Additionally, the analysis of cases where the substance was detected in drivers revealed an additional risk related to HHC consumption, especially concerning road safety. This information played a crucial role in the recommendation for the inclusion of the substance in Schedule II, reflecting a concern for public health and safety.

Impact on the Market and Industry

With the approval of the World Health Organization (WHO) recommendation, the HHC market, which currently operates similarly to THC in various countries, will be regulated more strictly. Although the substance has been widely marketed as a recreational alternative to THC, the UN's decision puts a definitive end to this non-medical use. The industry, which was already anticipating the decision, will have to adapt to the new reality, with severe restrictions on the production, distribution, and consumption of HHC.

Next Steps and Challenges for Signatory Countries

With the inclusion of HHC in Schedule II, all 184 signatory countries of the Convention on Psychotropic Substances will have the responsibility to incorporate this change into their national legislations. This will require the implementation of prescription systems for its use and strict oversight to ensure that HHC is used exclusively for scientific and medical purposes. This measure represents an additional challenge for countries in the fight against substance abuse and in promoting global public health.